Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-11-04

Clinical Trial Update: An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica [Phase 1, Phase 2]

View source ↗

Summary

An open-label Phase 1/2 trial evaluating eculizumab in neuromyelitis optica (Devic's disease) has completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SOLIRIS (eculizumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Neuromyelitis Optica, Devic's Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-11-04